SG11201406208QA - Polyinosinic-polycytidylic acid (poly (i:c)) formulations for the treatment of upper respiratory tract infections - Google Patents

Polyinosinic-polycytidylic acid (poly (i:c)) formulations for the treatment of upper respiratory tract infections

Info

Publication number
SG11201406208QA
SG11201406208QA SG11201406208QA SG11201406208QA SG11201406208QA SG 11201406208Q A SG11201406208Q A SG 11201406208QA SG 11201406208Q A SG11201406208Q A SG 11201406208QA SG 11201406208Q A SG11201406208Q A SG 11201406208QA SG 11201406208Q A SG11201406208Q A SG 11201406208QA
Authority
SG
Singapore
Prior art keywords
polyinosinic
formulations
poly
treatment
respiratory tract
Prior art date
Application number
SG11201406208QA
Other languages
English (en)
Inventor
Bruce Albert Malcolm
Roger Paulus Maria Sutmuller
Lieven Elvire Colette Baert
Original Assignee
Janssen Sciences Ireland Uc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48430695&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201406208Q(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Sciences Ireland Uc filed Critical Janssen Sciences Ireland Uc
Publication of SG11201406208QA publication Critical patent/SG11201406208QA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • A61K9/1623Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/17Immunomodulatory nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications
    • C12N2320/32Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Otolaryngology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201406208QA 2012-05-03 2013-05-02 Polyinosinic-polycytidylic acid (poly (i:c)) formulations for the treatment of upper respiratory tract infections SG11201406208QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12166595 2012-05-03
PCT/EP2013/059079 WO2013164380A1 (en) 2012-05-03 2013-05-02 Polyinosinic-polycytidylic acid (poly (i:c)) formulations for the treatment of upper respiratory tract infections

Publications (1)

Publication Number Publication Date
SG11201406208QA true SG11201406208QA (en) 2014-11-27

Family

ID=48430695

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201607288VA SG10201607288VA (en) 2012-05-03 2013-05-02 Polyinosinic-polycytidylic acid (poly (i:c)) formulations for the treatment of upper respiratory tract infections
SG11201406208QA SG11201406208QA (en) 2012-05-03 2013-05-02 Polyinosinic-polycytidylic acid (poly (i:c)) formulations for the treatment of upper respiratory tract infections

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201607288VA SG10201607288VA (en) 2012-05-03 2013-05-02 Polyinosinic-polycytidylic acid (poly (i:c)) formulations for the treatment of upper respiratory tract infections

Country Status (18)

Country Link
US (3) US9682096B2 (ru)
EP (1) EP2846767B1 (ru)
JP (1) JP6349304B2 (ru)
KR (1) KR102240042B1 (ru)
CN (1) CN104394846B (ru)
AU (1) AU2013255885C1 (ru)
BR (1) BR112014026957A8 (ru)
CA (1) CA2866230C (ru)
CL (1) CL2014002929A1 (ru)
CO (1) CO7101247A2 (ru)
ES (1) ES2911116T3 (ru)
HK (1) HK1203390A1 (ru)
IN (1) IN2014MN02359A (ru)
MX (1) MX2014013256A (ru)
NZ (1) NZ630040A (ru)
RU (1) RU2650636C2 (ru)
SG (2) SG10201607288VA (ru)
WO (1) WO2013164380A1 (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2846767B1 (en) 2012-05-03 2022-01-26 Janssen Sciences Ireland Unlimited Company Polyinosinic-polycytidylic acid (poly (i:c)) formulations for the treatment of upper respiratory tract infections
KR20160072140A (ko) * 2013-11-06 2016-06-22 얀센 사이언시즈 아일랜드 유씨 상기도 감염 치료용 폴리이노신산-폴리사이티딜산(폴리 (i:c)) 제형
GB201415381D0 (en) * 2014-08-29 2014-10-15 Algipharma As Inhalable powder formulations of alginate oligomers
AU2016259869A1 (en) * 2015-05-11 2017-11-30 Janssen Sciences Ireland Uc Polyinosinic-polycytidylic acid (Poly(I:C)) pea starch formulation for the prevention and/or treatment of upper respiratory tract infections
WO2017085228A1 (en) 2015-11-17 2017-05-26 Bioncotech Therapeutics, S.L Novel pharmaceutical composition comprising particles comprising a complex of a double-stranded polyribonucleotide and a polyalkyleneimine
CA3006563A1 (en) * 2015-11-30 2017-06-08 Catherine Crisp TURKEL Compositions and methods for otologic prophylaxis and treatment
US20200060972A1 (en) 2016-11-16 2020-02-27 Janssen Sciences Ireland Unlimited Company Formulations of polyinosinic acid and polycytidylic acid for the prevention of upper respiratory tract infections
CN110831581A (zh) 2017-05-17 2020-02-21 拜昂科技医疗公司 包含具有双链多核糖核苷酸和聚乙烯亚胺的复合物的粒子的新型药物组合物
EP3818990A4 (en) * 2018-06-29 2022-05-04 Xinfu (Beijing) Medical Technology Co., Ltd. METHOD OF MAKING AN IMMUNE RESPONSE ENHANCEMENT COMPOSITE

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8723846D0 (en) 1987-10-10 1987-11-11 Danbiosyst Ltd Bioadhesive microsphere drug delivery system
US5707644A (en) * 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
ATE154241T1 (de) 1991-10-01 1997-06-15 Takeda Chemical Industries Ltd Mikropartikeln-zusammenfassung zur verlängerten freigabe und herstellung derselbe
GB9606188D0 (en) * 1996-03-23 1996-05-29 Danbiosyst Uk Pollysaccharide microspheres for the pulmonary delivery of drugs
AR012448A1 (es) 1997-04-18 2000-10-18 Ipsen Pharma Biotech Composicion en forma de microcapsulas o de implantes que comprende un excipiente biodegradable, polimero o co-polimero, o una mezcla de talesexcipientes, y una sustancia activa o una mezcla de sustancias activas, procedimiento para la preparacion de una sustancia soluble en agua de elevada
CA2203843C (en) * 1997-04-28 2013-07-23 Her Majesty The Queen, In Right Of Canada, As Represented By The Ministe R Of National Defence Liposome-encapsulated poly iclc
MA25590A1 (fr) * 1998-09-14 2002-12-31 Inhale Therapeutic Syst Agent actif de delivraison de poudre seche
EP1322290A1 (en) * 2000-10-06 2003-07-02 Jagotec Ag Vaccine composition comprising an immunologically active substance embedded in microparticles consisting of starch with reduced molecular weight
AU2003287332A1 (en) 2002-11-01 2004-06-07 The Regents Of The University Of California Methods of treating pulmonary fibrotic disorders
US7638138B2 (en) 2003-02-21 2009-12-29 Translational Research, Ltd. Compositions for nasal administration of pharmaceuticals
AU2004263037B2 (en) 2003-08-11 2011-02-10 Japan As Represented By The Director-General Of National Institute Of Infectious Diseases Novel vaccine containing adjuvant capable of inducing mucosal immunity
JP4772693B2 (ja) * 2003-12-11 2011-09-14 ヴァックスデザイン・コーポレーション 免疫治療組成物、その製造方法及び使用方法
CN101229378A (zh) 2005-05-05 2008-07-30 国家淀粉及化学投资控股公司 用于送递活性剂的组合物
ATE539767T1 (de) 2005-06-08 2012-01-15 Yisheng Biopharma Singapore Pte Ltd Adjuvans auf basis von polyinosinsäure/polycytidylsäure
US20070166239A1 (en) * 2006-01-13 2007-07-19 Haixiang Lin Mucosal immunogenic substances comprising a polyinosinic acid - polycytidilic acid based adjuvant
GB0607534D0 (en) 2006-04-13 2006-05-24 Univ London Pharmacy Colonic drug delivery formulation
DK2046740T3 (da) 2006-07-22 2012-08-20 Oxagen Ltd Forbindelser med CRTH2-antagonistisk virkning
CL2007002218A1 (es) 2006-08-03 2008-03-14 Celgene Corp Soc Organizada Ba Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa.
AR067997A1 (es) 2007-08-24 2009-10-28 Novartis Ag Compuestos organicos
JP2009209086A (ja) 2008-03-04 2009-09-17 Masami Moriyama 粘膜投与型ワクチン
UA90013C2 (ru) * 2008-03-19 2010-03-25 Давид Анатолійович Нога Фармацевтическая композиция, содержащая инсулин, и способ его получения
EP2116602A1 (en) 2008-05-07 2009-11-11 Institut Gustave Roussy Combination products for treating cancer
EP2379059A4 (en) * 2008-12-10 2012-10-31 Anhui Zhongren Technology Co Ltd COMPOSITION WITH CONTROLLED RELEASE
CN101491503A (zh) 2008-12-17 2009-07-29 天津瑞普生物技术股份有限公司 一种用于宠物的聚肌胞滴丸及其制备方法
MX2011006720A (es) 2008-12-22 2011-10-06 Yissum Res Dev Co Vector de acido ribonucleico de cadena doble buscador del receptor del factor de crecimiento epidermico para el tratamiento sistemico del cancer.
CN101757018A (zh) * 2008-12-24 2010-06-30 天津瑞普生物技术股份有限公司 一种用于畜禽的聚肌胞干粉及其制备方法
AU2010232180B2 (en) 2009-03-31 2016-09-22 Japan As Represented By The Director-General Of National Institute Of Infectious Diseases Method for prophylaxis of influenza using vaccine for intranasal administration
WO2012013567A1 (en) 2010-07-28 2012-02-02 Boehringer Ingelheim International Gmbh Pharmaceutical composition for treatment of respiratory and inflammatory diseases
US8431155B1 (en) 2012-04-30 2013-04-30 Veroscience Llc Bromocriptine formulations
EP2846767B1 (en) 2012-05-03 2022-01-26 Janssen Sciences Ireland Unlimited Company Polyinosinic-polycytidylic acid (poly (i:c)) formulations for the treatment of upper respiratory tract infections
KR20160072140A (ko) 2013-11-06 2016-06-22 얀센 사이언시즈 아일랜드 유씨 상기도 감염 치료용 폴리이노신산-폴리사이티딜산(폴리 (i:c)) 제형

Also Published As

Publication number Publication date
US9682096B2 (en) 2017-06-20
US9987300B2 (en) 2018-06-05
US20150140042A1 (en) 2015-05-21
ES2911116T3 (es) 2022-05-17
EP2846767B1 (en) 2022-01-26
HK1203390A1 (en) 2015-10-30
NZ630040A (en) 2016-10-28
RU2650636C2 (ru) 2018-04-16
EP2846767A1 (en) 2015-03-18
JP2015515968A (ja) 2015-06-04
US20180325939A1 (en) 2018-11-15
AU2013255885A1 (en) 2014-09-25
MX2014013256A (es) 2015-01-16
CN104394846A (zh) 2015-03-04
JP6349304B2 (ja) 2018-06-27
BR112014026957A8 (pt) 2018-01-16
AU2013255885C1 (en) 2018-04-26
IN2014MN02359A (ru) 2015-08-14
WO2013164380A1 (en) 2013-11-07
BR112014026957A2 (pt) 2017-06-27
CA2866230A1 (en) 2013-11-07
SG10201607288VA (en) 2016-10-28
CA2866230C (en) 2020-08-18
RU2014148544A (ru) 2016-06-27
KR20150008855A (ko) 2015-01-23
AU2013255885B2 (en) 2017-10-05
CL2014002929A1 (es) 2015-01-16
CO7101247A2 (es) 2014-10-31
CN104394846B (zh) 2018-10-19
US10485816B2 (en) 2019-11-26
KR102240042B1 (ko) 2021-04-14
US20160296551A1 (en) 2016-10-13

Similar Documents

Publication Publication Date Title
SG11201406208QA (en) Polyinosinic-polycytidylic acid (poly (i:c)) formulations for the treatment of upper respiratory tract infections
DK3421042T3 (da) Indånding af nitrogenoxid til behandling af luftvejssygdomme
HK1208801A1 (en) Orally administered medical composition
ZA201403795B (en) Formulations for the treatment of diabetes
IL245412A0 (en) Polylinosinic-polycytidylic acid formulations for the treatment of upper respiratory tract infections
EP2931288A4 (en) TOPICAL FORMULATIONS FOR INCREASING THE DERMAL CONCENTRATION OF HYALURONIC ACID
PL2521562T3 (pl) Ev576 do zastosowania w leczeniu zakażeń wirusowych dróg oddechowych
HK1206623A1 (en) Pharmaceutical compositions and treatment of mastitis
HK1186671A1 (en) Formulations for the treatment of disorders of the upper respiratory tract
PL2934134T3 (pl) Zastosowania inhalacji kwasem acetylosalicylowym
IL232384A (en) Use of lupanate compounds or lupanic acid for the preparation of anti-gout drugs
HK1198746A1 (en) Medical device comprising boswellic acid
PL2939665T3 (pl) Kompozycja farmaceutyczna do leczenia zakażeń hiv
EP2594283A4 (de) Aerosolpräparat auf aprotininbasis zur behandlung von virusinfektionen der atemwege
EP2780051A4 (en) NEW IMPROVED FORMULATIONS FOR COATING MEDICAL DEVICES
PL2903608T3 (pl) Kompozycja farmaceutyczna obejmująca kwas propionowy do stosowania w leczeniu infekcji wirusowych
ZA201308905B (en) Nasal pharmaceutical formulation comprising fluticasone
PT2814462T (pt) Composição farmacêutica com base em óleo para o tratamento de doenças gastrointestinais
HUP1200552A2 (en) Pharmaceutical compositions for the treatment of high blood pressure
HK1196953A1 (zh) 用於治療糖尿病的製劑
GB201207476D0 (en) pharmaceutical for the treatment of leishmaniasis
GB201201778D0 (en) Treatment of inflammatory respiratory disease
HUP1100245A2 (en) Pharmaceutical composition for the treatment of wounds